Blog

Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer

Raffaele Colombo/LinkedIn

Oct 4, 2024, 17:28

Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer

Raffaele Colombo shared a post on X:

“sBLA for trastuzumab deruxtecan (T-DXd) has been accepted by FDA (and granted Priority Review) for patients with HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining < IHC 1+) breast cancer after at least one endocrine therapy, based on DESTINY-Breast06.”

Source: Raffaele Colombo/X

Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.

Breast Cancer cancer cancer awareness cancer care DESTINY-Breast06 FDA fight against cancer Global fight against cancer HER2 OncoDaily Oncology Raffaele Colombo

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity